Catalyst Pharmaceuticals Sees FY24 Revenue $475M-$485M Vs $473.67 Est.
Catalyst Pharmaceuticals Sees FY24 Revenue $475M-$485M Vs $473.67 Est.
catalyst pharmaceuticals預計2024財年營業收入爲47500萬-48500萬美元，預計爲473.67美元。
- Expect total revenues for the full year 2024 to be between $475 million and $485 million, which includes the $2.1 million milestone payment received from DyDo that is included in License and other revenue.
- Revising full-year 2024 net product revenue guidance for FIRDAPSE to be between $300 million and $310 million; reaffirming FYCOMPA net product revenue guidance to be between $130 million and $135 million; and increasing AGAMREE net product revenue guidance to be between $40 million and $45 million, respectively.
- Revising full year research and development ("R&D") expense guidance to less than $15 million due to delays in the timing of certain R&D related initiatives.
- 預計2024財年的總營業收入將介於47500萬美元和48500萬美元之間，其中包括從DyDo獲得的210萬美元里程碑付款，已計入許可和其他收入。
- 修訂2024財年FIRDAPSE淨產品營收指導範圍爲30000萬美元至31000萬美元；重申FYCOMPA淨產品營收指導範圍爲13000萬美元至13500萬美元；分別將AGAMREE淨產品營收指導範圍提高到4000萬美元至4500萬美元。
- 由於某些與研發相關的項目的實施時間延遲，將2024財年研究與開發（"R&D"）支出指導修訂爲少於1500萬美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間